Icure Pharma to raise capital via third-party allocation
아이큐어
175250
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2414
Risk-adjusted indicator based on 2414 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Previous major shareholder: Choi Young-kwon (13.6% stake)
- • New major shareholder: SoluM Cosmetic Co., Ltd. (35.31% stake)
- • Withholding tax payment related to embezzlement: Approximately 8 billion KRW
- • Mandatory lock-up period for new shares: 1 year
- • Post-lock-up transfer restriction: 70% (14,352,031 Shares) for 1 year
AI Analysis Summary
Icure Pharmaceutical Inc. has decided on a paid-in capital increase via third-party allocation. The primary purpose is to normalize accounts receivable and payable cycles and restore operating cash flow, following an approximately 8 billion KRW withholding tax payment in 2026 related to a former CEO's embezzlement. This capital increase will result in a change of the largest shareholder from Choi Young-kwon (13.6%) to SoluM Cosmetic Co., Ltd. (35.31%). New shares will be subject to a 1-year mandatory lock-up, with 70% (14,352,031 Shares) restricted for another year post-lock-up. The company aims to resolve financial uncertainties and stabilize governance. The stock trading is currently suspended.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.